Liposomal Bupivicaine (Exparel) for Pain Control During Care of Rib Fractures

NCT02390440 Phase 4 WITHDRAWN

This study is looking at a novel therapy of numbing medication injected directly around the fracture site. The purpose of this study is to determine if the study medication, EXPAREL®, is a viable alternative to current therapies for rib fractures.

Details

Lead sponsor	Michael Moncure, MD
Phase	Phase 4
Status	WITHDRAWN
Start date	2015-04
Completion	2017-01

Conditions

• Pain

Interventions

• EXPAREL

Primary outcomes

• Pain relief (visual analog scale) — Change from Treatment to Hour 72
  pain relief as measured by visual analog scale and patient satisfaction survey, before and after drug administration

Countries

United States